- Home
- WINA vs AUPH Comparison
WINA vs AUPH Comparison
Compare WINA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINA
- AUPH
- Stock Information
- Founded
- WINA 1988
- AUPH 1993
- Country
- WINA United States
- AUPH Canada
- Employees
- WINA N/A
- AUPH N/A
- Industry
- WINA Other Specialty Stores
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- WINA Consumer Discretionary
- AUPH Health Care
- Exchange
- WINA Nasdaq
- AUPH Nasdaq
- Market Cap
- WINA 1.5B
- AUPH 1.6B
- IPO Year
- WINA 1993
- AUPH 1999
- Fundamental
- Price
- WINA $422.12
- AUPH $15.33
- Analyst Decision
- WINA
- AUPH Strong Buy
- Analyst Count
- WINA 0
- AUPH 3
- Target Price
- WINA N/A
- AUPH $17.67
- AVG Volume (30 Days)
- WINA 70.1K
- AUPH 1.9M
- Earning Date
- WINA 10-15-2025
- AUPH 11-04-2025
- Dividend Yield
- WINA 2.69%
- AUPH N/A
- EPS Growth
- WINA 2.56
- AUPH N/A
- EPS
- WINA 11.21
- AUPH 0.55
- Revenue
- WINA $84,517,400.00
- AUPH $265,808,000.00
- Revenue This Year
- WINA $7.05
- AUPH $17.33
- Revenue Next Year
- WINA $3.60
- AUPH $14.31
- P/E Ratio
- WINA $37.66
- AUPH $27.90
- Revenue Growth
- WINA 3.35
- AUPH 20.62
- 52 Week Low
- WINA $295.79
- AUPH $6.55
- 52 Week High
- WINA $527.37
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- WINA 46.55
- AUPH 71.77
- Support Level
- WINA $410.11
- AUPH $13.34
- Resistance Level
- WINA $439.87
- AUPH $15.98
- Average True Range (ATR)
- WINA 16.86
- AUPH 0.82
- MACD
- WINA 2.92
- AUPH 0.23
- Stochastic Oscillator
- WINA 67.78
- AUPH 79.95
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.